

ASX: CVB

28 August 2024

CURVEBEAM AI SUCCESSFULLY COMPLETES RETAIL ENTITLEMENT OFFER

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB “**CurveBeam AI**” or the “**Company**”) is today pleased to announce the completion of the retail component of its 1-for-6 pro-rata accelerated non-renounceable entitlement offer (“**ANREO**”) of new fully paid ordinary shares (“**New Shares**”) in the capital of the Company at an issue price of \$0.18 per New Share (“**Retail Entitlement Offer**”).

The Retail Entitlement Offer closed at 5:00pm (AEST) on Thursday, 22 August 2024 (“**Retail Closing Date**”) with valid applications received for 9,126,773 New Shares (including under the top-up facility). Each eligible retail shareholder that subscribed for additional New Shares under the top-up facility will receive the full allocation of additional New Shares for which they applied, subject to compliance with all applicable laws.

The entitlements of ineligible retail shareholders and entitlements not taken up by eligible retail shareholders represent 11,221,191 New Shares (“**Shortfall Shares**”), which will be the subject of a shortfall offer (as set out in section 6 of the Retail Entitlement Offer Booklet dated 8 August 2024 (“**Offer Booklet**”). The Company’s Board of Directors may issue the Shortfall Shares to third parties, including current shareholders or new investors, within three months after the Retail Closing Date. Further details about the proposed allocation of Shortfall Shares is set out in section 6 of the Offer Booklet.

The total of approximately \$1.64 million raised under the Retail Entitlement Offer, combined with the \$9.9 million raised under the Institutional Entitlement Offer and Institutional Placement (as announced to ASX on 5 August 2024) will bring the total proceeds of the capital raising to approximately \$11.54 million to date. The second tranche of the Institutional Placement (raising approximately \$2 million) is subject to shareholder approval at a general meeting of the Company, which is expected to be held in late September 2024 or early October 2024.

CEO Greg Brown said “We are very pleased with the outcome from the overall raise at \$11.54 million providing funding for the launch of the enhanced HiRise. Following the targeted validation for robotic surgery systems in Q1, the Company will move into supporting our US distribution partner to address the key obstacles they have had in closing sales opportunities. HiRise placements, along with the launch of the first BMD annuity model, post FDA clearance, will help us to deliver the shareholder value that lies in our market opportunity”.

The New Shares will be issued today and are expected to commence trading on ASX tomorrow, 29 August 2024. New Shares will rank equally with existing Shares in all respects from their date of issue.

Authorised for release by Greg Brown, the Chief Executive Officer.

About CurveBeam AI Limited

CurveBeam AI Limited (ABN 32 140 706 618) (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

CEO and Managing Director:

Greg Brown
info@curvebeamai.com

Investor / media enquiries contact:

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

For personal use only